inflammatory potential News
-
Predicting the inflammatory potential of nanoparticles
New methods to screen nanoparticles for potential toxicity to humans are needed to test the growing number of engineered nanoparticles being developed. A battery of simple tests has been developed that can be used to investigate the potential of nanoparticles to cause lung inflammation and also avoids the need for animal testing. Despite the many benefits of using nanomaterials, concerns have ...
-
World Health Organization Panel Strongly Recommends The Use Of Baricitinib To Treat Hospitalised Patients With COVID-19
On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids. BenevolentAI first identified baricitinib as a COVID-19 treatment candidate in January 2020 using its artificial intelligence (AI) platform. BenevolentAI was able to rapidly pinpoint ...
By Benevolent
-
Kannalife Secures New INCI Name for its Prospective Anti-Inflammatory and Antioxidant Ingredient Atopidine
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the receipt of a designated International Nomenclature Cosmetic Ingredient (INCI) name for the Company’s patent-pending molecule and flagship consumer product to be sold under the trademark ...
-
Runway Growth Capital Announces a Senior Secured Term Loan of $35 Million to SetPoint Medical
Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies seeking an alternative to raising equity, today announced the close of a senior secured term loan of $35 million to SetPoint Medical (“SetPoint”), a Valencia, California based, privately-held clinical-stage bioelectronic medicine company developing ...
-
Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in ...
-
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral blood flow in this ...
-
Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine
DOYLESTOWN, Pa., April 01, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ...
-
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of Postoperative Recovery Following Primary Hip or Knee Arthroplasty
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in AKST6021-211, a phase 2 clinical trial of its proprietary human plasma fraction, GRF6021, administered before and after primary hip or knee arthroplasty, to provide key insights into the immunomodulatory effects of ...
-
TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE
A new study with TikoMed’s platform lead clinical drug candidate ILB®, provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of Amyotrophic Lateral Sclerosis (ALS). The study was published in PLOS ONE today. In a phase II study of ILB administered to patients with ALS for five weeks, the ...
By TIKOMED AB
-
Empowering Research Excellence: Alfa Chemistry's THEIC, D-Pantethine, and Methoxytriethyleneoxypropyltrimethoxysilane at the Forefront
In the realm of scientific research, the pursuit of excellence is often driven by the quest for innovative solutions and groundbreaking discoveries. Alfa Chemistry, a leading global supplier of research chemicals, has been at the forefront of empowering researchers with the highest quality products. Among the newest additions to its extensive catalog are THEIC, D-Pantethine, and ...
-
Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis
Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced a $112 million Series C financing. This financing will be used to advance its portfolio of programs and the company’s first clinical trials, further establishing its leadership in the gut-brain axis field. All investors from the Series ...
-
Neurent Medical Receives FDA Clearance for NEUROMARK, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis
GALWAY, Ireland–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). The clearance gives clinicians access to an in-office treatment designed to create lesions to disrupt the posterior nasal nerves, ...
-
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has outperformed cannabidiol (CBD) in preventing inflammatory ...
-
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD
DOYLESTOWN, Pa., April 14, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you